【Information on JSMO2025（1/2）】
Call for Abstracts has begun‼
We look forward to receiving submissions from you all.

📌Abstract Submission Period: Noon, Friday, June 14, 2024 – Noon, Tuesday, September 17, 2024 (JST)

📌Website URL: site2.convention.co.jp/jsmo2025/engli…

#JSMO2025

Last Chance - Join us tomorrow 6/14 for a webinar that will delve into the most groundbreaking studies/updates presented at the ASCO 2024 meeting. A webinar w/focus on pivotal advancements in the treatment & management of #lungcancer . Register Here: bit.ly/ASCO24Web #LCSM

🗓️REGISTER NOW‼️
🔥 #ASCO24 HIGHLIGHTS Webinar
🌟IASLC Education Committee
🎙️Chair Dr. Rebecca Heist
✅ADRIATIC: Alissa Cooper, MD
✅REACH-PC: Dr. Joseph Greer
✅LAURA: Zosia Piotrowska
#LCSM #LCWEBINARS OncoAlert
iaslc.org/meetings-webin…

‼️NEVER MISS IT‼️
🎯OncoAlert NewsLetter is coming SOON🔜
🔥COMPLET #ASCO24 coverage
🔥Best way to wrap up a huge wave of #ASCO24
🔥＃LCSM
✅CROWN👑in #LungCancer
✅EVOKE01🫁
✅LAURA
✅ADRIATIC🌊
and more.

📤Submitted‼️
Looking forward to seeing you all in Hong Kong 🇭🇰
#LCSM IASLC OncoAlert

Last Chance - Submit Your #ACLC24 Abstract Before June 7 at midnight! Showcase your research, & contribute to discussions that shape the future of treatments in #lungcancer /thoracic malignancies. Build connections w/colleagues from around the world! bit.ly/ACLC24-AbSub #LCSM

Only 1 Day to Go – #WCLC24 Early Bird Discounted Registration ends tomorrow Friday June 7, at midnight! Don’t miss the opportunity to engage in crowdsourced interactive workshops, and so much more! Register Today and Save: bit.ly/WCLC24Reg #LCSM #IASLC50

Join us on 6/14 for an exclusive webinar that will delve into the most groundbreaking studies & updates presented at the recent ASCO 2024 meeting. A webinar w/focus on pivotal advancements in the treatment & management of #lungcancer . Register Here: bit.ly/ASCO24Web #LCSM

Only 3 Days to Go – #WCLC24 Early Bird Discounted Registration ends on Friday June 7, at midnight! Expand your horizons - incredible networking opportunities with thousands of delegates from all over the world! Register Today and Save: bit.ly/WCLC24Reg #LCSM #IASLC50

Conversations sparked. Connections made. More than 45,000 attendees came together at #ASCO24 to explore the art & science of oncology and left inspired to change the future of cancer care. Thanks to all who joined us!

Save the date for #ASCO25 : May 30–June 3, 2025

🎯NEVER MISS IT‼️
#ASCO24 Day4⃣ OncoAlert NewsLetter
🔥Best way to wrap up a huge wave of #ASCO24

🔥 #ASCO24 #LCSM Oral
🎙️Brilliant discussion by donington
🎯CheckMate 77T, GASTO-1091, TALENT
✅Value of LDCT screening
✅In-depth analyses of perioperative ICI in single/multi N2
✅Greatest benefit in those with the highest risk of micro-metastases
OncoAlert ASCO

🔥 #ASCO24 #LCSM Oral
🎙️Great discussion by Melina Marmarelis
🎯BEAT-SC, BEAT-meso, Neo-Adj IO in MPM
✅Value of additive with IO and anti-VEGF
✅Checklists when PFS was not translated into OS
✅Treatment choice in unresectable pleural mesothelioma
OncoAlert ASCO

🔥 #ASCO24 #LCSM Oral
🔥#8009 Lung cancer screening in heavy smokers (HS) and non-smokers with lung cancer family history (LCFH)
🎙️Dr. Pan-Chyr Yang
🎯LCFH showed a📈detection compared to HS
✅🇹🇼National Screening
OncoAlert ASCO

🔥 #ASCO24 #LCSM Oral
🔥 #LBA8007 CheckMate 77T: Perioperative nivo by nodal status
🎙️Dr. Tina Cascone
🎯EFS N2 HR 0.42, non-N2 0.60
🎯Downstage 67% (ypN0 57%)
🎯pCR N2 29% (multi-station N2 38%)
✅Primary: EFS
✅NCT04025879
OncoAlert ASCO

🔥 #ASCO24 #LCSM Oral
🔥#8005 MRD (RaDaR® assay NeoGenomics) from ADAURA
🎙️A/Prof Tom John
🎯Sens.: 65% (62 MRD+/96 DFS+), spec.: 95% (118 MRD–/124 DFS–)
🎯Median lead time 4.7m
✅Phase III
✅Primary: DFS
✅NCT02511106
OncoAlert ASCO

🔥 #ASCO24 #LCSM Oral
🔥#8003 Phase I study of neo-adj nivo +chemo for resectable pleural mesotheliomas
🎙️Michael Offin
🎯18 out of 19 pts underwent surgery ≤30 days
✅Phase I
✅Primary: Feasibility
✅NCT04162015
#LCSM OncoAlert ASCO

🔥 #ASCO24 #LCSM Oral
🔥#8001 BEAT-SC: Bevacizumab or placebo with IMpower 133 in ES-SCLC
🎙️Dr. Yuichiro Ohe
🎯PFS HR 0.70 (95%CI: 0.54-0.90)
🎯OS HR 1.22 (95%CI: 0.89-1.67)
✅Phase III
✅Primary: PFS
✅jRCT2080224946
#LCSM OncoAlert ASCO

🔥 #ASCO24 #LCSM Oral
🔥 #LBA8002 BEAT-meso (ETOP 13-18): Bevacizumab + Chemo +/- atezolizumab
🎙️Sanjay Popat
🎯OS HR 0.84 (95%CI 0.66-1.06), PFS HR 0.72 (95%CI 0.59-0.89)
🎯Epithelioid OS HR 1.00, Non-Epithel OS HR 0.50
✅Primary: OS
✅NCT03762018
OncoAlert ASCO

🔥 #ASCO24 Highlights of the Day III #LCSM
🎙️Patrick Forde
🎯3 selected abstracts
✅BEAT-meso: Bev + Cx +/- Atezo in MPM
🎙️Sanjay Popat
✅LAURA: Osi after CRT in stage III EGFRm
🎙️Suresh S. Ramalingam, MD, FASCO
✅ADRIATIC: Durva after CRT in LS-SCLC
🎙️David R. Spigel, MD, FASCO
OncoAlert ASCO